---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-24-000105"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:24:40.651471+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook

## Summary
- Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.
- GAAP diluted EPS $0.30; adjusted diluted EPS $0.93.
- Raised full-year 2024 revenue and adjusted diluted EPS guidance.
- Franco Poletti named President of Cardiopulmonary Business Unit, effective August 1, 2024.
- Plans to pursue CMS coverage for VNS Therapy in RECOVER patient population; reducing 2025 investment in difficult-to-treat depression.

## SEC filing metadata
- accession: 0001639691-24-000105
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000105/0001639691-24-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000105/livn-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-24-000105
- JSON: https://secwatch.observer/filing/0001639691-24-000105.json
- Plain text: https://secwatch.observer/filing/0001639691-24-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.